source
- CSL Vifor warns Tavneos exit from Europe will cut revenue by about 25%CSL Vifor’s parent company CSL Limited said the withdrawal of the drug Tavneos from the European market creates a significant headwind for sales. The company expects its revenue to fall by roughly…
- Kolon TissueGene cuts 37 jobs after phase 3 osteoarthritis trial failsKolon TissueGene announced it will lay off 37 employees at its Maryland headquarters, with the reductions set to take effect at the end of August. The cuts follow a phase 3 trial of the company’s…